Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P40145
UPID:
ADCY8_HUMAN
Alternative names:
ATP pyrophosphate-lyase 8; Adenylate cyclase type VIII; Adenylyl cyclase 8; Ca(2+)/calmodulin-activated adenylyl cyclase
Alternative UPACC:
P40145
Background:
Adenylate cyclase type 8, also known as ATP pyrophosphate-lyase 8, plays a pivotal role in cAMP formation in response to calcium entry, thereby activating cAMP signaling pathways. This process influences synaptic plasticity, insulin secretion, and various brain functions including learning, memory, and anxiety modulation. It is central to insulin secretion by regulating glucose homeostasis and enhances PTGER4-mediated PLA2 secretion.
Therapeutic significance:
Understanding the role of Adenylate cyclase type 8 could open doors to potential therapeutic strategies.